01 1Cipla Ltd.
02 1Glaxo Wellcome Manufacturing Pte. Ltd
01 1CABOTEGRAVIR SODIUM
02 1Cabotegravir Sodium
01 1India
02 1United Kingdom
NDC Package Code : 53104-7741
Start Marketing Date : 2023-11-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 52482-018
Start Marketing Date : 2019-12-23
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
A Cabotegravir Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cabotegravir Sodium, including repackagers and relabelers. The FDA regulates Cabotegravir Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cabotegravir Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cabotegravir Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cabotegravir Sodium supplier is an individual or a company that provides Cabotegravir Sodium active pharmaceutical ingredient (API) or Cabotegravir Sodium finished formulations upon request. The Cabotegravir Sodium suppliers may include Cabotegravir Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Cabotegravir Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cabotegravir Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cabotegravir Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cabotegravir Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cabotegravir Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cabotegravir Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cabotegravir Sodium suppliers with NDC on PharmaCompass.
LOOKING FOR A SUPPLIER?